Dr. Tim Cripe, M.D. Ph.D

Imagine if there was a legal performance enhancing drug that makes you strong enough to resist getting sick from an infection? Even better, you only take it once and you are stronger for life! #vaccinessavelives #preventionisthebestmedicine #legalPED

.⁦@nationwidekids⁩ ⁦@OhioState⁩ ⁦@StudentLifeOSU⁩ ⁦@BuckeyeThon⁩ #FTK

What a compelling essay. Thank you Craig for being will to share your personal story.

Congrats to our collaborative group enabled by the @theNCI PI-DDN.

@AstroGrower @FutureJurvetson @vironexis Phase 1 clinicaltrials.gov/study/NCT06533…

@FutureJurvetson @vironexis @KidsOncDoc Sounds promising. And would be revolutionary if it delivers. What’s the trial phase ? Preclinical? Phase I?

Imagine directing the liver to become a factory to crank out personalized immunotherapies for most cancers and prevent them from spreading. Vironexis came out of stealth today with FDA clearance to begin the first-ever clinical trial of an AAV-delivered cancer immunotherapy. By delivering instructions for the body to do continuous manufacturing, it just takes a single dose and is much less expensive than current gene therapies. FD: we co-led their seed financing. From their press release: “Steve Jurvetson, Co-Founder of Future Ventures, added, ‘We were drawn not only to the novelty of the TransJoin technology but also to its broad applicability, spanning treatments for blood-based cancers, solid tumor metastasis prevention, and cancer vaccines, as well as immune disorders. The versatility of this platform is truly extraordinary.”  — vironexis.com/vironexis-biot… And a great backstory article on the clinical need: “Vironexis Biotherapeutics' mission seems lofty and impressive — treating cancer with gene therapy. But the heart of the biotech, which emerged from stealth Thursday with $26 million in seed funding, was born from Timothy Cripe's desire to make it a little easier for children with leukaemia to take their medication. As the chief of the division of paediatric haematology and oncology at Nationwide Children's Hospital, Cripe said children often have to receive continuous infusions of bispecific T-cell engagers (BiTEs) that last for weeks due to their short half-life, requiring patients to wear specialised backpacks to carry around a bag of the drug. Hospital visits are frequent to readjust tubing if it slips out, or to replace the syringe. Cripe's idea to eliminate the drug's cumbersome administration was to develop a one-time treatment that would give the liver long-lasting instructions to make the cancer therapy itself. According to CEO Varma, 90% of deaths caused by cancer can be attributed to metastasis, which occurs when a primary tumour sheds circulating cells. By administering the gene therapy before a tumour has the chance to metastasise, the generated bispecifics act as cancer-killing sentries that patrol the bloodstream for any sign of circulating tumour cells. And if a BiTE finds one, ‘it zaps the cell before it has a chance to embed,’ he described. The company's second-most advanced programme, VNX-202, is slated to enter the clinic next year and is intended to prevent HER2+ breast cancers from metastasising.” — firstwordpharma.com/story/5894733 Company site just went live too: vironexis.com

Great article by Elizabeth Eaton in @fwpharma about our platform technology, pipeline and mission to transform cancer treatment for patients with AAV-delivered T-cell immunotherapy! See article: firstwordpharma.com/story/5894733

Thank you @nationwidekids and @vironexis and especially my outstanding laboratory team at NCH including Mark Currier, Brian Hutzen, Pin-Yi Wang, Chun-Yu Chen, & Andrea Glaspell for making great progress so far! vironexis.com

Congrats to Dr Paudel for publishing his PhD thesis work from our lab in Frontiers | Myelomodulatory treatments augment the therapeutic benefit of oncolytic viroimmunotherapy in murine models of malignant peripheral nerve sheath tumors #MPNST #NF1 #TVEC frontiersin.org/journals/immun…

Congrats to all graduating ⁦@nationwidekids⁩ hematology/oncology/BMT fellows, especially our 4th year sarcoma fellow Dr Alejandra Rosales, shown here with the sarcoma team doctors. They are lucky to get you ⁦@LSUHealthNO⁩ in Shreveport as a new Assistant Professor!

We still need books

Thanks to @nationwidekids Dr Kevin Cassady for leading this study showing IL12 gene therapy improves oncolytic viroimmunotherapy in preclinical models of #MPNST #sarcoma frontiersin.org/journals/immun…

Congrats to @nationwidekids Dr Mark Ranalli shown here presenting interim results at #ASCO24 of his clinical trial using adoptive NK cells for pediatric patients with #neuroblastoma (STING) being run through NANT based on our NCH colleague Dr Dean Lee’s work

Thanks to #childhoodcancer research luminaries Drs Jim Armatruda, Brenda Weigel, and Mark Hatley for being external advisors to our ⁦@nationwidekids⁩ @theNCI⁩ funded T32 training program and thanks to our trainees for giving inspiring research talks today! #cancerlauNCH

We are pleased to have ⁦@NeuroOncDoc⁩ delivering our @nationwidekids #childhoodcancer T32 lecture today on the #glioma microenvironment and how he hopes to prevent malignant transformation of low grade to high grade

Reviving the lost art of meeting reports - ScienceDirect sciencedirect.com/science/articl…

Progress in sarcomas: Highlights from the 2023 annual meetingof the Co... sciencedirect.com/science/articl…

⁦@OhioState⁩ About to give a graduate lecture at The Ohio State University without a virtual option - talk about old school! I hope students show up….! #oldfashioned #vintage #inpersonrocks

It’s a fantastic day for our patients! Thank you for the partnership @OSUCCC

.⁦@nationwidekids⁩ welcomes ⁦⁦@BuckeyeThon⁩ tonight!

Congrats to @OhioState Molecular Cellular Developmental Biology PhD candidate Emily Franz comentored by me @nationwidekids and Dr Ryan Roberts @KidCancerLab for her poster award at the international sarcoma mtg in Dublin Ireland #CTOS hopefully she will be submitting paper soon!